Received FDA Clearance for the HeartBeam System – an At-Home, High-Fidelity Heart Monitoring Technology Commenced Early Access Program to Attain Key Insights and Establish Sales Funnel in Preparation for Commercialization Submitted 510(k) Application to FDA for Groundbreaking 12-lead Electrocardiogram (ECG) Synthesis Software Gross Proceeds of ~$11.5 Million from Public Offering and Over-Allotment Option to Fund Near-Term... Read More

SANTA CLARA, Calif. / Mar 06, 2025 / Business Wire / HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced that CEO Robert Eno and CFO Timothy Cruickshank will be participating in the following upcoming conferences in Dana Point, CA. 37th Annual Roth Conference being held at The Laguna Cliffs Marriott Resort & Spa, March... Read More

SANTA CLARA, Calif. / Feb 27, 2025 / Business Wire / HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, will hold a conference call on Thursday, March 13, 2025 at 4:30 p.m. Eastern time to discuss its results for the fourth quarter and full year ended December 31, 2024, and will be providing updates on regulatory initiatives,... Read More

Additional gross proceeds of approximately $1.5 Million Follows successful closing of $10 million underwritten offering Funding is part of the Company’s strategic plan focusing on key growth milestones and preparation for U.S. commercialization SANTA CLARA, Calif. / Feb 25, 2025 / Business Wire / HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful... Read More

HeartBeam system was recently cleared by the U.S. Food and Drug Administration (FDA) for comprehensive arrhythmia assessment 510(k) application submitted to the FDA for the Company’s groundbreaking 12-lead electrocardiogram (ECG) synthesis software Funding is part of the Company’s strategic plan focusing on key growth milestones and preparation for U.S. commercialization SANTA CLARA, Calif. / Feb 13, 2025 / Business Wire /... Read More

SANTA CLARA, Calif. / Jan 29, 2025 / Business Wire / HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced it has submitted a 510(k) application to the U.S. Food and Drug Administration (FDA) for the Company’s groundbreaking 12-lead electrocardiogram (ECG) synthesis software designed for the assessment of rhythms and... Read More

HeartBeam system was recently cleared by US Food and Drug Administration (FDA) for comprehensive arrhythmia assessment The Company is gearing up for an Early Access Program to gain initial commercialization learnings SANTA CLARA, Calif. / Dec 23, 2024 / Business Wire / HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced that... Read More

First cable-free, ambulatory ECG that captures the heart’s electrical signals from three distinct directions for high-fidelity data collection and advanced diagnostics Patients can have the credit card-sized device with them at all times, ready to record an ECG whenever they feel symptoms and reduce delays in care Company to initiate Early Access Program to gain important patient and physician feedback on the use of the... Read More

The studies further strengthen HeartBeam’s body of clinical evidence for its portable, cable-free, credit card-sized device that is designed to be capable of synthesizing a 12-lead ECG The first study is a pilot study demonstrating similar performance of HeartBeam’s vector-based ambulatory technology to standard 12-lead ECGs for arrhythmia detection The second study is a feasibility study highlighting the potential of... Read More

Continued Clinical and Regulatory Progress on the HeartBeam System Key Appointments to Management Team Completed as Part of Planned Evolution in Preparation for US Commercialization Strengthening Clinical Evidence Base, with Two Additional Studies to be Presented at the American Heart Association Conference in November 2024 Management to Host Webcast and Conference Call Today at 4:30 p.m. ET SANTA CLARA, Calif. / Nov 07,... Read More

SANTA CLARA, Calif. / Oct 31, 2024 / Business Wire / HeartBeam, Inc . (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights wherever the patient is, will hold a conference call on Thursday, November 7, 2024 at 4:30 p.m. Eastern time to discuss its results for the third quarter ended September 30, 2024, and will be providing regulatory updates, reviewing... Read More

Company Receives Top Honors in the ‘Home Health Diagnostic’ Category for its Groundbreaking Technology that Captures the Heart’s Electrical Signals from Three Dimensions SANTA CLARA, Calif. / Oct 24, 2024 / Business Wire / HeartBeam, Inc . (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights wherever the patient is, announced today its selection as a winner... Read More

Industry leader brings extensive experience in developing go-to-market strategies for breakthrough products and delivering growth Founder and current CEO Branislav Vajdic named President to focus on advancing the Company’s groundbreaking vector-based technology for heart health, including AI applications SANTA CLARA, Calif. / Oct 17, 2024 / Business Wire / HeartBeam, Inc . (NASDAQ: BEAT), a medical technology company focused... Read More

Industry Leader, Former Head of Data Science at Verily (Google Life Sciences) and Globally Respected Authority on Artificial Intelligence (AI) Applications in Biosensor Technologies Dr. Myers to Drive Innovation and Strategic Growth as HeartBeam Advances and Expands its AI Capabilities SANTA CLARA, Calif. / Sep 24, 2024 / Business Wire / HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming... Read More

Seasoned MedTech Leader with Proven Track Record of Strategic Planning, Financial Stewardship and Commercial Success SANTA CLARA, Calif. / Sep 10, 2024 / Business Wire / HeartBeam, Inc . (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights wherever the patient is, announced the appointment of Timothy Cruickshank as Chief Financial Officer (CFO), effective... Read More

Continued Clinical and Regulatory Progress on the HeartBeam AIMIGo™ System Enrollment Complete in VALID-ECG Clinical Study That Will Be the Basis of the Upcoming FDA Submission on the 12-Lead Synthesis Software Management to Host Webcast and Conference Call Today at 4:30 p.m. ET SANTA CLARA, Calif. / Aug 14, 2024 / Business Wire / HeartBeam, Inc . (NASDAQ: BEAT), a medical technology company focused on transforming cardiac... Read More

SANTA CLARA, Calif. / Aug 01, 2024 / Business Wire / HeartBeam, Inc . (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, will hold a conference call on Wednesday, August 14, 2024 at 4:30 p.m. Eastern time to discuss its results for the second quarter ended June 30, 2024, and will be providing regulatory updates, reviewing ongoing initiatives, and... Read More

SANTA CLARA, Calif. / Jul 01, 2024 / Business Wire / HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, today announced that it has been added to the Russell Microcap® Index effective after the market close on June 28, 2024 as part of FTSE Russell’s annual reconstitution. The annual Russell US Indexes reconstitution captures the 4,000... Read More

New Data Presented at Heart Rhythm Society Conference Demonstrates Continued Progress with Company’s AI Program Data Show That Applying AI to VCG Data Provides More Consistent and Reliable Detection of Atrial Flutter SANTA CLARA, Calif. / May 20, 2024 / Business Wire / HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, today announced... Read More

Prestigious International Annual Awards Program Recognizes Standout Digital Health & Medical Technology Products and Companies SANTA CLARA, Calif. / May 13, 2024 / Business Wire / HeartBeam, Inc . (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, today announced that HeartBeam AIMIGo™ has been selected as winner of the “Best New ECG Technology... Read More

Continued Clinical and Regulatory Progress on the AIMIGo™ 3D VECG System Presented Positive Results on its Artificial Intelligence Capabilities for Detecting Arrhythmias Management to Host Webcast and Conference Call Today At 4:30 p.m. ET SANTA CLARA, Calif. / May 09, 2024 / Business Wire / HeartBeam, Inc . (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized... Read More

SANTA CLARA, Calif. / Apr 25, 2024 / Business Wire / HeartBeam, Inc . (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, will hold a conference call on Thursday May 9, 2024 at 4:30 p.m. Eastern time to discuss its results for the first quarter ended March 31, 2024, and will be providing regulatory updates, reviewing ongoing initiatives, and... Read More

New Data Presented at the European Heart Rhythm Association Conference Marks First Scientific Presentation on HeartBeam AI, the Company’s Deep Learning Technology Data Shows HeartBeam AI Combined with VCG Greatly Improves Detection of Atrial Flutter over Single-Lead ECGs Found in Leading Smartwatches and Other Wearables SANTA CLARA, Calif. / Apr 09, 2024 / Business Wire / HeartBeam, Inc. (NASDAQ: BEAT), a medical technology... Read More

First Patients Enrolled in Pivotal Study Evaluating AIMIGo™ System for Synthesizing a 12-Lead ECG Ongoing Clinical and Regulatory Progress for the AIMIGo 3D VECG System Recently Received 2 New Patents for our Proprietary Technologies Management to Host Webcast and Conference Call Today At 4:30 p.m. ET SANTA CLARA, Calif. / Mar 20, 2024 / Business Wire / HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on... Read More

VALID-ECG Study will Form the Basis of the Company’s Upcoming FDA 510(k) Submission SANTA CLARA, Calif. / Mar 14, 2024 / Business Wire / HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, announced today that it has enrolled the first patients in the VALID-ECG ( Clinical Validation of the AIMIGo 12-Lead ECG Synthesis Software for... Read More

Company Continues Expanding its Intellectual Property Footprint, Now has 14 US and 4 International Patents SANTA CLARA, Calif. / Mar 07, 2024 / Business Wire / HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, announced today that it has received two new patents on its core vectorelectrocardiography (VECG) technology from the United... Read More

SANTA CLARA, Calif. / Mar 05, 2024 / Business Wire / HeartBeam, Inc . (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, will hold a conference call on Wednesday March 20, 2024 at 4:30 p.m. Eastern time to discuss its results for the fourth quarter and full fiscal year ended December 31, 2023, and will be providing regulatory updates, reviewing... Read More

Company Appoints Mohammad Shokoohi-Yekta to Lead Program and Industry Pioneer Lance Myers as Advisor SANTA CLARA, Calif. / Dec 14, 2023 / Business Wire / HeartBeam, Inc . (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, today announced significant developments for the use of artificial intelligence (AI) applied to its proprietary... Read More

Strengthens Leadership with Appointments to Executive Team and Boards Publishes Landmark Peer-Reviewed Article, Validating Technology Ongoing Clinical and Regulatory Progress for the HeartBeam AIMIGo™ VECG Device Management to Host Webcast and Conference Call Today At 4:30 p.m. ET SANTA CLARA, Calif. / Nov 14, 2023 / Business Wire / HeartBeam, Inc . (NASDAQ: BEAT), a cardiac technology company that has developed the first... Read More

Company Adds Leading Cardiologists to Provide Strategic Insights SANTA CLARA, Calif. / Nov 09, 2023 / Business Wire / HeartBeam, Inc . (NASDAQ: BEAT), a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (VECG) platform for patient use at home, allowing for the creation of rich data for AI, today announced the expansion of its Scientific Advisory Board (SAB) to... Read More

New Patent Extends Intellectual Property Footprint for Company’s Groundbreaking Technology in Large ECG Patch Monitor Market SANTA CLARA, Calif. / Nov 07, 2023 / Business Wire / HeartBeam, In c. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only credit card-size, portable 3D-vector electrocardiogram (VECG) platform that is always with the patient, allowing for the creation of rich data for AI,... Read More

SANTA CLARA, Calif. / Oct 31, 2023 / Business Wire / HeartBeam, Inc . (NASDAQ: BEAT), a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (VECG) platform for patient use at home, allowing for the creation of rich data for AI, will hold a conference call on Tuesday November 14, 2023 at 4:30 p.m. Eastern time to discuss its results for the third quarter ended... Read More

Medical device industry veteran, Jon Hunt , will lead the next phase of growth for Implicity as demand for remote cardiac monitoring and data management solutions soars CAMBRIDGE, Mass. , Sept. 27, 2023 /PRNewswire/ -- Implicity , a leader in remote patient monitoring (RPM) and cardiac data management solutions, announced that Jon Hunt , PhD., has joined the company as its new Chief Commercial Officer (CCO), North America.... Read More

Experienced Leaders to Support Clinical Development and Commercialization of HeartBeam’s Ambulatory VECG Products SANTA CLARA, Calif. / Sep 26, 2023 / Business Wire / HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (VECG) platform for patient use at home, allowing for the creation of rich data for AI, has appointed Richa Gujarati... Read More

Further Strengthens Board of Directors and IP Position, Publishes First Peer-Reviewed Article Management to Host Webcast and Conference Call Today At 4:30 p.m. ET SANTA CLARA, Calif. / Aug 10, 2023 / Business Wire / HeartBeam, Inc . (NASDAQ: BEAT), a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (VECG) platform for patient use at home, allowing for the creation... Read More

Study Comparing 3D VECG Approach to Conventional 12L ECG Appeared in JACC: Advances, a Journal of the American College of Cardiology SANTA CLARA, Calif. / Aug 09, 2023 / Business Wire / HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (VECG) platform for patient use at home, allowing for the creation of rich data for AI, today... Read More

Experienced Biomedical Engineer Brings 12+ Years’ Experience in Regulatory Affairs and Quality Assurance for Medical Devices and Diagnostics with FDA and in the Private Sector SANTA CLARA, Calif. / Aug 08, 2023 / Business Wire / HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (VECG) platform for patient use at home, allowing for... Read More

SANTA CLARA, Calif. / Jul 27, 2023 / Business Wire / HeartBeam, Inc . (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform intended for patient use at home, will hold a conference call on Thursday August 10, 2023 at 4:30 p.m. Eastern time to discuss its results for the second quarter ended June 30, 2023, and will be reviewing recent announcements,... Read More

Renowned Vascular Physician and Researcher Brings Wealth of Clinical and Industry Experience to Board SANTA CLARA, Calif. / Jul 26, 2023 / Business Wire / HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform intended for patient use at home, today announced the appointment of Michael R. Jaff, DO to its board of directors, effective as... Read More

Accomplished Medical Technology Leader and Veteran Investor Bring Strategic Experience and Vision to Board SANTA CLARA, Calif. / Jun 08, 2023 / Business Wire / HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform intended for patient use at home, today announced the appointment of Ken Nelson and Mark Strome to its board of directors,... Read More

SANTA CLARA, Calif. / May 30, 2023 / Business Wire / HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform intended for patient use at home, today announced that it has entered into a Strategic Alliance Agreement (SAA) with Samsung, extending the existing SAA between LIVMOR and Samsung. HeartBeam acquired the assets of LIVMOR earlier... Read More

Patent Underscores AI for Vectorcardiography (VECG) IP Leadership Effort SANTA CLARA, Calif. / May 25, 2023 / Business Wire / HeartBeam, Inc . (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D vector electrocardiogram (VECG) platform intended for patient use at home, today announced it has received a notice of allowance from The United States Patent and Trademark Office for a key patent... Read More

Submission Seeks Clearance for the Company’s 3D Vector Electrocardiogram Device SANTA CLARA, Calif. / May 18, 2023 / Business Wire / HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D vector electrocardiogram (VECG) platform intended for patient use at home, today announced it has submitted a 510(k) application to the U.S. Food and Drug Administration (FDA) for its HeartBeam... Read More

Closed $26.5 Million with a Public Offering and Registered Direct Offering to Enable Company to Execute on Upcoming Clinical, Regulatory and Commercial Milestones and Extend Cash Runway into Late 2024 Strategic Focus on Becoming the Global Leader in Ambulatory Vectorcardiography, the Highest Resolution ECG Monitoring Platform Management to Host Webcast and Conference Call Today At 4:30 p.m. ET SANTA CLARA, Calif. / May 11,... Read More

HeartBeam to Focus on Becoming the Global Leader in Ambulatory Vectorcardiography, the Highest Resolution ECG Monitoring Platform Funding to Enable Company to Execute on Upcoming Clinical, Regulatory and Commercial Milestones, Extends Cash Runway into Late 2024 HeartBeam to Host Conference Call to Discuss Financing, Strategic Initiatives and First Quarter 2023 Financial Results on Thursday May 11, 2023 at 4:30 p.m. ET SANTA... Read More

SANTA CLARA, Calif. / Mar 16, 2023 / Business Wire / HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D vector electrocardiogram (VECG) platform for heart attack detection anytime, anywhere, has reported its financial and operational results for the fourth quarter and full year ended December 31, 2022. Fourth Quarter and Subsequent 2023 Operational Highlights Strategic... Read More

SANTA CLARA, Calif. / Mar 14, 2023 / Business Wire / HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform for heart attack detection anytime, anywhere, today announced the strategic acquisition of substantially all assets from LIVMOR, a digital health solutions company providing a patient-engaging remote monitoring system of critical... Read More

SANTA CLARA, Calif. / Mar 08, 2023 / Business Wire / HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform for heart attack detection anytime, anywhere, has announced a senior leadership change ahead of key milestones in 2023 including FDA clearance for the HeartBeam AIMI™ system and FDA submission of the HeartBeam AIMIGo™ 3D vector ECG... Read More

SANTA CLARA, Calif. / Mar 02, 2023 / Business Wire / HeartBeam, Inc . (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform for heart attack detection anytime, anywhere, will hold a conference call on Thursday March 16, 2023 at 4:30 p.m. Eastern time to discuss its results for the fourth quarter and full fiscal year ended December 31, 2022, and will be... Read More

Senior Medical Technology Executive to Enhance Company’s Strategic and Operations Capabilities SANTA CLARA, Calif. / Jan 24, 2023 / Business Wire / HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform for heart attack detection anytime, anywhere, announced today the appointment of Robert Eno to the newly created position of President.... Read More

Patented Technology Provides Protection for HeartBeam AIMIGo™ Credit Card-sized Device in European Market HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, announced today that its patent that enables generation of a synthesized 12-lead ECG by the HeartBeam AIMIGo™ credit card-sized device was issued by the... Read More

HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform for heart attack detection anytime, anywhere, today issued a letter to shareholders from its Chief Executive Officer and Founder, Branislav Vajdic, PhD. Dear Fellow Shareholders, 2022... Read More